Status:
UNKNOWN
Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis
Lead Sponsor:
Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara
Conditions:
Coronavirus Infections
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
We have to be aware of the challenge and concerns brought by 2019-nCoV to our healthcare workers. Front-line healthcare workers can become infected in the management of patients with COVID-19; the hig...
Detailed Description
The study is a open-blind, randomised trial that will be conducted in asymptomatic professionals working in areas of high exposure and high risk of transmission of SARS-COV-2. After obtaining fully i...
Eligibility Criteria
Inclusion
- Aged 18 - 70 years;
- Professionals working in areas of high exposure and high risk of transmission of SARS-COV-2;
- Understands and agrees to comply with planned study procedures;
- Signed informed consent for participation in the study.
Exclusion
- Pregnancy or breastfeeding;
- Major allergy to Hidroxychloroquine, chloroquine or 4-aminoquinolines;
- Serum potassium lower than 3.4 mEq/l;
- Serum magnesium lower than 1.7 mg/dL;
- QTc interval \> 470 ms for man and \> 480 ms for woman;
- Weight \< 40 kg;
Key Trial Info
Start Date :
July 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2021
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04384458
Start Date
July 20 2020
End Date
April 1 2021
Last Update
October 6 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Drug Research and Development Center (NPDM), Federal University of Ceará (UFC)
Fortaleza, Ceará, Brazil, 60430-275